Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $1.48, $0.19 worse than the analyst estimate of $1.67. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.4 billion.

• Gilead reiterates its full year 2018 guidance

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.